ESPE Abstracts

Background: In 2017, the Endocrine Society published guidelines for the endocrine treatment of gender dysphoria/ gender incongruence. Adolescents who meet diagnostic criteria for gender dysphoria undergo pubertal suppression using gonadotropin-releasing hormone analogs (GnRHa) and induction of puberty with gender-affirming hormonal therapy. Blood pressure (BP) monitoring prior to and during treatment with GnRHa in transgender adolescents is recommended. This r...

Background: The QT interval, corrected for sex and heart rate (QTc), measures the duration of the cardiac action potential and can indicate the risk of arrhythmias. The QT interval is typically longer in women compared to men; a phenomenon often attributed to estrogen's effects. However, conflicting data exist regarding the effects of gonadotropin-releasing hormone agonist (GnRHa) and gender-affirming hormonal treatment (GAHT) on QT intervals and dispersi...

Context: Given the importance of sex hormones in metabolic regulation, dynamics in body composition and cardiometabolic alterations may occur in transgender persons receiving gender-affirming hormone (GAH) therapy.Objectives: Our aim was to explore the association between muscle-to-fat ratio (MFR) and the risk for metabolic syndrome components in transgender youth.Methods: In 71 tr...

Context: Higher frequency of atypical gender identity, non-heterosexual fantasies and sexual relationships, and cross-gender role behavior has been reported in females with the more severe salt wasting form of congenital adrenal hyperplasia (CAH). Data on these aspects and quality of life (QOL) among the milder, more prevalent form, the non-classic CAH (NCCAH) is scarce.Objective: To assess gender identity, gender role, ...